Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up - Here's Why

Key Points

• Shares gapped up pre-market: SGIOY opened at $11.20 after a $10.75 close and was last quoted around $10.685 with roughly 2,651 shares traded.
• Earnings and revenue beat: Quarterly results showed EPS of $0.28 versus $0.19 expected and revenue of $966.5M versus $848.4M expected, with a 41.8% net margin and 13.7% ROE.
• Solid financial and valuation profile: Market cap about $18.3B, P/E 14.13 and PEG 1.05, very strong liquidity (quick ratio 5.21, current ratio 5.84) and near-zero leverage (debt/equity 0.01).

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $10.75, but opened at $11.20. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $10.6850, with a volume of 2,651 shares changing hands.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

The stock has a fifty day moving average of $10.31 and a two-hundred day moving average of $9.18. The stock has a market cap of $18.28 billion, a price-to-earnings ratio of 14.13, a price-to-earnings-growth ratio of 1.05 and a beta of 0.17. The company has a quick ratio of 5.21, a current ratio of 5.84 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last posted its quarterly earnings results on Friday, January 30th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of $0.19 by $0.09. The business had revenue of $966.53 million for the quarter, compared to analysts' expectations of $848.42 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.82% and a return on equity of 13.70%. On average, equities research analysts anticipate that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 earnings per share for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company's product portfolio spans both established and innovative therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.